pharmaphorum

JUNE 2, 2022

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. By 2026, the report predicts that each of the top 10 selling orphan drugs will earn between $3 billion and $13 billion.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. Capturing market share.

Compounding 98

Compounding Insurance Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52